Literature DB >> 26631631

Immune history profoundly affects broadly protective B cell responses to influenza.

Sarah F Andrews1, Yunping Huang1, Kaval Kaur2, Lyubov I Popova1, Irvin Y Ho1, Noel T Pauli2, Carole J Henry Dunand1, William M Taylor1, Samuel Lim1, Min Huang1, Xinyan Qu1, Jane-Hwei Lee1, Marlene Salgado-Ferrer1, Florian Krammer3, Peter Palese4, Jens Wrammert5, Rafi Ahmed5, Patrick C Wilson6.   

Abstract

Generating a broadly protective influenza vaccine is critical to global health. Understanding how immune memory influences influenza immunity is central to this goal. We undertook an in-depth study of the B cell response to the pandemic 2009 H1N1 vaccine over consecutive years. Analysis of monoclonal antibodies generated from vaccine-induced plasmablasts demonstrated that individuals with low preexisting serological titers to the vaccinating strain generated a broadly reactive, hemagglutinin (HA) stalk-biased response. Higher preexisting serum antibody levels correlated with a strain-specific HA head-dominated response. We demonstrate that this HA head immunodominance encompasses poor accessibility of the HA stalk epitopes. Further, we show polyreactivity of HA stalk-reactive antibodies that could cause counterselection of these cells. Thus, preexisting memory B cells against HA head epitopes predominate, inhibiting a broadly protective response against the HA stalk upon revaccination with similar strains. Consideration of influenza exposure history is critical for new vaccine strategies designed to elicit broadly neutralizing antibodies.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26631631      PMCID: PMC4770855          DOI: 10.1126/scitranslmed.aad0522

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  53 in total

1.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

2.  Relating influenza virus membrane fusion kinetics to stoichiometry of neutralizing antibodies at the single-particle level.

Authors:  Jason J Otterstrom; Boerries Brandenburg; Martin H Koldijk; Jarek Juraszek; Chan Tang; Samaneh Mashaghi; Ted Kwaks; Jaap Goudsmit; Ronald Vogels; Robert H E Friesen; Antoine M van Oijen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

3.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

4.  Rapid development of broadly influenza neutralizing antibodies through redundant mutations.

Authors:  Leontios Pappas; Mathilde Foglierini; Luca Piccoli; Nicole L Kallewaard; Filippo Turrini; Chiara Silacci; Blanca Fernandez-Rodriguez; Gloria Agatic; Isabella Giacchetto-Sasselli; Gabriele Pellicciotta; Federica Sallusto; Qing Zhu; Elisa Vicenzi; Davide Corti; Antonio Lanzavecchia
Journal:  Nature       Date:  2014-10-05       Impact factor: 49.962

5.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.

Authors:  Hugo Mouquet; Johannes F Scheid; Markus J Zoller; Michelle Krogsgaard; Rene G Ott; Shetha Shukair; Maxim N Artyomov; John Pietzsch; Mark Connors; Florencia Pereyra; Bruce D Walker; David D Ho; Patrick C Wilson; Michael S Seaman; Herman N Eisen; Arup K Chakraborty; Thomas J Hope; Jeffrey V Ravetch; Hedda Wardemann; Michel C Nussenzweig
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

6.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

Review 7.  Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Curr Opin Virol       Date:  2013-08-24       Impact factor: 7.090

8.  High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination.

Authors:  Kaval Kaur; Nai-Ying Zheng; Kenneth Smith; Min Huang; Lie Li; Noel T Pauli; Carole J Henry Dunand; Jane-Hwei Lee; Michael Morrissey; Yixuan Wu; Michelle L Joachims; Melissa E Munroe; Denise Lau; Xinyan Qu; Florian Krammer; Jens Wrammert; Peter Palese; Rafi Ahmed; Judith A James; Patrick C Wilson
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

9.  Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses.

Authors:  Yuval Avnir; Aimee S Tallarico; Quan Zhu; Andrew S Bennett; Gene Connelly; Jared Sheehan; Jianhua Sui; Amr Fahmy; Chiung-yu Huang; Greg Cadwell; Laurie A Bankston; Andrew T McGuire; Leonidas Stamatatos; Gerhard Wagner; Robert C Liddington; Wayne A Marasco
Journal:  PLoS Pathog       Date:  2014-05-01       Impact factor: 6.823

10.  Endogenous antigen tunes the responsiveness of naive B cells but not T cells.

Authors:  Julie Zikherman; Ramya Parameswaran; Arthur Weiss
Journal:  Nature       Date:  2012-09-06       Impact factor: 49.962

View more
  179 in total

1.  Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance.

Authors:  Yao-Qing Chen; Linda Yu-Ling Lan; Min Huang; Carole Henry; Patrick C Wilson
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 2.  Immune history and influenza virus susceptibility.

Authors:  Sarah Cobey; Scott E Hensley
Journal:  Curr Opin Virol       Date:  2017-01-12       Impact factor: 7.090

Review 3.  What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Is Affinity Maturation a Self-Defeating Process for Eliciting Broad Protection?

Authors:  Christopher T Stamper; Patrick C Wilson
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

Review 4.  The evolution of seasonal influenza viruses.

Authors:  Velislava N Petrova; Colin A Russell
Journal:  Nat Rev Microbiol       Date:  2017-10-30       Impact factor: 60.633

5.  Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.

Authors:  Seth J Zost; Nicholas C Wu; Scott E Hensley; Ian A Wilson
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 6.  Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire.

Authors:  Joel Finney; Akiko Watanabe; Garnett Kelsoe; Masayuki Kuraoka
Journal:  Immunol Rev       Date:  2019-09-27       Impact factor: 12.988

7.  A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.

Authors:  Takuya Yamamoto; Yuji Masuta; Masatoshi Momota; Masaru Kanekiyo; Tomohiro Kanuma; Shoukichi Takahama; Eiko Moriishi; Yasuhiro Yasutomi; Takashi Saito; Barney S Graham; Yoshimasa Takahashi; Ken J Ishii
Journal:  Int Immunol       Date:  2019-02-15       Impact factor: 4.823

Review 8.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

Review 9.  Immunological responses to influenza vaccination: lessons for improving vaccine efficacy.

Authors:  Taia T Wang; Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Curr Opin Immunol       Date:  2018-05-10       Impact factor: 7.486

Review 10.  A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.

Authors:  Boopathy Ramakrishnan; Karthik Viswanathan; Kannan Tharakaraman; Vlado Dančík; Rahul Raman; Gregory J Babcock; Zachary Shriver; Ram Sasisekharan
Journal:  Trends Microbiol       Date:  2016-10-14       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.